Thursday, June 23rd, 2016 adds ‘Epithelial Ovarian Cancer Pipeline Review H1 2016’ Market Research to its database, providing in-depth, high quality, transparent and market-driven, expert’s analysis.

In-detail Table of Contents of Epithelial Ovarian Cancer Pipeline Market

Companies involved in this research AbbVie Inc., Adaptimmune Therapeutics Plc, Amgen Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, Atara Biotherapeutics, Inc., Bayer AG, BioNumerik Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Celon Pharma Sp. z o.o., Celsion Corporation, CerRx, Inc., Cerulean Pharma, Inc., Clovis Oncology, Inc., Dr. Reddy's Laboratories Limited, EirGenix Inc., Eisai Co., Ltd., Eli Lilly and Company, Exelixis, Inc., Genentech, Inc., Genor BioPharma Co., Ltd., Glycotope GmbH, Ignyta, Inc., ImmunoGen, Inc., Incyte Corporation, Innate Immunotherapeutics Ltd, Johnson & Johnson, Juno Therapeutics Inc., Mabion SA, MabVax Therapeutics Holdings, Inc., MedImmune, LLC, Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Mycenax Biotech Inc., Novartis AG, Oasmia Pharmaceutical AB, OBI Pharma, Inc., Oncobiologics, Inc., Oncolix, Inc., Oncolytics Biotech Inc., Otsuka Holdings Co., Ltd., Oxford BioMedica Plc, OXiGENE, Inc., Pfizer Inc., Pharma Mar, S.A., Pharmacyclics, Inc., Prima BioMed Ltd., PsiOxus Therapeutics Limited, Quest PharmaTech Inc., Sanofi, Sanofi Pasteur SA, Shenzen SiBiono GeneTech Co., Ltd., Sotio a.s., Synta Pharmaceuticals Corp., Tara Immuno-Oncology Therapeutics LLC, Tesaro, Inc., TetraLogic Pharmaceuticals, Tyrogenex, Inc., VentiRx Pharmaceuticals, Inc., and ViiV Healthcare Limited

Get discount on this research at .

Scope for this research:

  • The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer
  • The report reviews pipeline therapeutics for Epithelial Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Epithelial Ovarian Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Epithelial Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Epithelial Ovarian Cancer

The report provides comprehensive information on the therapeutics under development for Epithelial Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epithelial Ovarian Cancer and features dormant and discontinued projects.

Complete research report at .

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

File Library

Contact Profile

RnR Market Research

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus:



RSS / Feeds:

Ritesh Tiwari
P: + 1 888 391 5441


Epithelial Ovarian Cancer Pipeline, Epithelial Ovarian Cancer Pipeline market, Epithelial Ovarian Cancer Pipeline market research, Epithelial Ovarian Cancer Pipeline market outlook, Epithelial Ovarian Cancer Pipeline market forecast, Epithelial Ovarian Ca




More Formats

View QR Code